Ackermans & van Haaren: Results capping already strong subsidiary reporting. DPS beat. Fagron: Acquisition of Pharmavit Europe, active in nutraceutical raw materials. Fugro: Patience please. Kendrion: Sees signs of improvement in EU economy. Proximus: 2026 dividend halved, 2028-30 targets a bit better on lower capex. Proximus: 4Q25 in line EBITDA on weaker sales, FCF up; 2026 guidance below on EBITDA. Recticel: Strong FY25 results, CEO transition seen as a negative
Ackermans & van Haaren ends a successful year 2025 with a net profit of 593 million euros (+29%) Dear shareholder, Dear Madam, Dear Sir, Please find attached our press release with the FY2025 Results: Outstanding results at DEME, Delen Private Bank, Bank Van Breda and SIPEF boost net profit to 592.5 million euros.Equity strengthens to 5.7 billion euros, delivering a 10.3% return on equityProposal to increase the dividend to 4.60 euros per share (+21%) Best regards Ackermans & van Haaren Attachment
Ackermans & van Haaren clôture un excellent exercice 2025 avec un bénéfice net de 593 millions d'euros (+29%) Cher actionnaire, Monsieur, Madame, Veuillez trouver ci-joint notre communiqué concernant nos résultats annuels 2025: Les excellents résultats de DEME, Delen Private Bank, la Banque Van Breda et SIPEF propulsent le bénéfice net à 592,5 millions d'eurosLes fonds propres se renforcent à 5,7 milliards d'euros, générant ainsi un rendement des fonds propres de 10,3 %.Proposition d'augmenter le dividende à 4,60 euros par action (+21%) Meilleures salutations, Ackermans & van Haare...
Ackermans & van Haaren sluit een succesvol jaar af met een nettowinst van 593 miljoen euro (+29%) Geachte aandeelhouder, Geachte mevrouw, geachte heer, Gelieve bijgevoegd ons persbericht over de jaarresultaten 2025 te vinden. Uitmuntende resultaten bij DEME, Delen Private Bank, Bank Van Breda en SIPEF stuwen de nettowinst naar 592,5 miljoen euroEigen vermogen versterkt tot 5,7 miljard euro, waardoor AvH 10,3% rendement op eigen vermogen levertVoorstel om het dividend te verhogen tot 4,60 euro per aandeel (+21%) Met vriendelijke groeten, Ackermans & van Haaren Bijlage ...
The Citrini report is an interesting thought experiment. It qualifies fully as neo-marxist, calling for the tendency of profit rates to fall. Like Marx 165 years ago, the authors are nevertheless getting a couple of things wrong. Click the link below for our thoughts and our perspective on the matter.
Aalberts: In-line FY25, but low quality / AMG: 4Q25 beat by 7%; in-line 2026 guidance / Bekaert: In-line 2025, cautious outlook for 2026 to result in c.8% consensus cut / CMB.TECH: A small bit beat but not the full story / Corbion: Dividend sweetener / CTP: Q4 results lighter due to some delays; stronger 2026 outlook / DEME: Strong FY25 numbers and FY26 outlook / Elia Group: Preview FY25 results / SBM Offshore: Another step-up in shareholder return / Syensqo: Substantial miss in 4Q25; FY26 outlo...
FY25 adj EBITDA increased by 27% organically and was close to our and consensus forecasts. FY26 guidance of a c. 100bps adj EBITDA margin improvement to around 17% is no surprise (KBCS 16.7%, CSS 16.9%). We remind that Corbion is conducting a strategic review on PLA which we believe will most likely result in an exit of Corbion, while still remaining the lactic acid supplier to the buyer. Biochemicals will be de-emphasized, which will put the growth focus on food preservation and formulation, al...
Over 4Q25, CMB.TECH reported a net profit of $90.1m ($0.31 p.s.). Corrected for $49.5m capital gains on vessel disposals the adjusted EBITDA was $272.5m well above our $215m forecast. A $0.16 p.s. interim dividend was declared. 1Q26 to date fixtures point to a strong start of the year and leave considerable upside to our assumptions. While the crude tanker rates are making headlines daily, we are impressed by the solid fixtures and rates in dry bulk, which makes up >50% of GAV. The contract back...
CMB.TECH ANNOUNCES Q4 2025 RESULTS - EIGHT VLCCS SOLD AT STELLAR PRICES CMB.TECH ANNOUNCES Q4 2025 RESULTSEIGHT VLCCS SOLD AT STELLAR PRICES ANTWERP, Belgium, 26 February 2026 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its unaudited financial results today for the fourth quarter ended 31 December 2025. HIGHLIGHTSFinancial highlights: Profit for the period of USD 90.1 million in Q4 2025. EBITDA for the same period was USD 322 million.CMB.TECH’s contract backlog increased by USD 304 million to USD 3.05 bi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.